{"disease":{"id":"neoplasms-ovarian","name":"neoplasms ovarian"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03598946","title":"Urinary Human Papilloma Virus Test in the General Population in Brittany","phase":"NA","overall_status":"UNKNOWN","enrollment_count":12500,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04235556","title":"Integrated Care Pathway in Oncology (PASSION)","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03602859","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT07035587","title":"Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04188652","title":"Diagnosing Ovarian Cysts - the DOC Study","phase":"","overall_status":"COMPLETED","enrollment_count":1123,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT07318558","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01847274","title":"A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT04111978","title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Swiss GO Trial Group","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02354586","title":"A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":463,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT05172310","title":"PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT02494037","title":"The Canadian/US Integrative Oncology Study","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"The Canadian College of Naturopathic Medicine","has_results":false},{"nct_id":"NCT04593381","title":"Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"Gemelli Molise Hospital","has_results":false},{"nct_id":"NCT03842982","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Centre Oscar Lambret","has_results":false},{"nct_id":"NCT05763511","title":"Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05242861","title":"Retrospective Study of Brachytherapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT01905592","title":"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":216,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT04351139","title":"Impact of the COVID-19 Pandemic in Gynecological Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05610501","title":"Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06819215","title":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Zhejiang Yangli Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT05180474","title":"GEN1047 for Solid Tumors - First in Human (FIH) Trial","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":179,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT03112733","title":"Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":171,"lead_sponsor_name":"Ilker Kahramanoglu","has_results":false},{"nct_id":"NCT01478685","title":"A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT04892342","title":"Study of ESG401 in Adults With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Shanghai Escugen Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03593681","title":"Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT05059782","title":"Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT03648489","title":"Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT02657889","title":"Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT00086567","title":"Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03371693","title":"Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT06543537","title":"Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04665921","title":"A Study of SGN-STNV in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":111,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT02786524","title":"Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT05613088","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06885697","title":"Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05605535","title":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT03858166","title":"Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":68,"lead_sponsor_name":"Shandong University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}